Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Glutamatergic modulation of auditory information processing in the human brain.

Gunduz-Bruce H, Reinhart RM, Roach BJ, Gueorguieva R, Oliver S, D'Souza DC, Ford JM, Krystal JH, Mathalon DH.

Biol Psychiatry. 2012 Jun 1;71(11):969-77. doi: 10.1016/j.biopsych.2011.09.031. Epub 2011 Oct 29.

2.

Haloperidol counteracts the ketamine-induced disruption of processing negativity, but not that of the P300 amplitude.

Oranje B, Gispen-de Wied CC, Westenberg HG, Kemner C, Verbaten MN, Kahn RS.

Int J Neuropsychopharmacol. 2009 Jul;12(6):823-32. doi: 10.1017/S1461145708009814. Epub 2009 Jan 21.

PMID:
19154656
3.

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC.

Arch Gen Psychiatry. 2000 Dec;57(12):1139-47.

PMID:
11115327
4.

Translating the Rosetta Stone of N-acetylcysteine.

Dean OM, Bush AI, Berk M.

Biol Psychiatry. 2012 Jun 1;71(11):935-6. doi: 10.1016/j.biopsych.2012.04.001. No abstract available.

PMID:
22579303
5.

The effects of ketamine on the mismatch negativity (MMN) in humans - A meta-analysis.

Rosburg T, Kreitschmann-Andermahr I.

Clin Neurophysiol. 2016 Feb;127(2):1387-94. doi: 10.1016/j.clinph.2015.10.062. Epub 2015 Nov 23.

PMID:
26699665
6.

Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients.

Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, Bovet P, Bush AI, Conus P, Copolov D, Fornari E, Meuli R, Solida A, Vianin P, Cuénod M, Buclin T, Do KQ.

Neuropsychopharmacology. 2008 Aug;33(9):2187-99. Epub 2007 Nov 14.

7.

Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia.

Roser P, Haussleiter IS, Chong HJ, Maier C, Kawohl W, Norra C, Juckel G.

Psychopharmacology (Berl). 2011 Dec;218(4):611-20. doi: 10.1007/s00213-011-2352-y. Epub 2011 May 18.

PMID:
21590281
8.

Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice.

Ehrlichman RS, Maxwell CR, Majumdar S, Siegel SJ.

J Cogn Neurosci. 2008 Aug;20(8):1403-14. doi: 10.1162/jocn.2008.20097.

PMID:
18303985
9.

Ketamine effects on brain function--simultaneous fMRI/EEG during a visual oddball task.

Musso F, Brinkmeyer J, Ecker D, London MK, Thieme G, Warbrick T, Wittsack HJ, Saleh A, Greb W, de Boer P, Winterer G.

Neuroimage. 2011 Sep 15;58(2):508-25. doi: 10.1016/j.neuroimage.2011.06.045. Epub 2011 Jun 29.

PMID:
21723949
10.

Effect of ketamine on the neuromagnetic mismatch field in healthy humans.

Kreitschmann-Andermahr I, Rosburg T, Demme U, Gaser E, Nowak H, Sauer H.

Brain Res Cogn Brain Res. 2001 Aug;12(1):109-16.

PMID:
11489614
11.

Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.

Krystal JH, Abi-Saab W, Perry E, D'Souza DC, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A.

Psychopharmacology (Berl). 2005 Apr;179(1):303-9. Epub 2004 Aug 10.

PMID:
15309376
12.

Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.

Heekeren K, Daumann J, Neukirch A, Stock C, Kawohl W, Norra C, Waberski TD, Gouzoulis-Mayfrank E.

Psychopharmacology (Berl). 2008 Jul;199(1):77-88. doi: 10.1007/s00213-008-1129-4. Epub 2008 May 18.

13.

The effects of a sub-anaesthetic dose of ketamine on human selective attention.

Oranje B, van Berckel BN, Kemner C, van Ree JM, Kahn RS, Verbaten MN.

Neuropsychopharmacology. 2000 Mar;22(3):293-302.

14.

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, Breier A.

Neuropsychopharmacology. 1996 May;14(5):301-7.

15.

Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.

Umbricht D, Koller R, Vollenweider FX, Schmid L.

Biol Psychiatry. 2002 Mar 1;51(5):400-6.

PMID:
11904134
16.

Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments.

Schmidt A, Bachmann R, Kometer M, Csomor PA, Stephan KE, Seifritz E, Vollenweider FX.

Neuropsychopharmacology. 2012 Mar;37(4):865-75. doi: 10.1038/npp.2011.261. Epub 2011 Oct 26.

17.

Nicotine fails to attenuate ketamine-induced cognitive deficits and negative and positive symptoms in humans: implications for schizophrenia.

D'Souza DC, Ahn K, Bhakta S, Elander J, Singh N, Nadim H, Jatlow P, Suckow RF, Pittman B, Ranganathan M.

Biol Psychiatry. 2012 Nov 1;72(9):785-94. doi: 10.1016/j.biopsych.2012.05.009. Epub 2012 Jun 19.

PMID:
22717030
18.

Separate and combined effects of low dose ketamine and nicotine on behavioural and neural correlates of sustained attention.

Knott VJ, Millar AM, McIntosh JF, Shah DK, Fisher DJ, Blais CM, Ilivitsky V, Horn E.

Biol Psychol. 2011 Sep;88(1):83-93. doi: 10.1016/j.biopsycho.2011.06.012. Epub 2011 Jul 13.

PMID:
21742012
19.

Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists.

Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH.

Arch Gen Psychiatry. 2000 Mar;57(3):270-6.

PMID:
10711913
20.

Effects of clozapine on auditory event-related potentials in schizophrenia.

Umbricht D, Javitt D, Novak G, Bates J, Pollack S, Lieberman J, Kane J.

Biol Psychiatry. 1998 Oct 15;44(8):716-25.

PMID:
9798075

Supplemental Content

Support Center